Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat insomnia, which is marketed under the brand name of Ambien or Stilnox; and invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.09809161079954809 | N/A |
Market Cap | $69.79M | N/A |
Shares Outstanding | 711.48M | 29.45% |
Employees | 0 | N/A |
Shareholder Equity | 3.78M | -50.37% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -6.86 | N/A |
P/S Ratio | 254.17 | N/A |
P/B Ratio | 18.46 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -1.8221 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $274.59K | N/A |
Earnings | -$6.89M | N/A |
EPS | -0.0143 | N/A |
Earnings Yield | -0.1458 | N/A |
Gross Margin | 0.4986 | N/A |
Operating Margin | -23.85 | N/A |
Net income margin | -25.08 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $3.70M | N/A |
Cash on Hand | $3.50M | N/A |
Debt to Equity | 0.3026 | 113.57% |
Current Ratio | $3.22 | -26.18% |